Last reviewed · How we verify
Imrestor (PEGBOVIGRASTIM)
Imrestor (PEGBOVIGRASTIM) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) analog. It is used to treat chemotherapy-induced neutropenia. Imrestor is a pegylated version of bovine GM-CSF, which is a protein that stimulates the production of white blood cells. It is currently owned by Sandoz, a Novartis division, and is available as a branded product. Key safety considerations include the risk of hypersensitivity reactions and the potential for increased risk of thrombosis.
At a glance
| Generic name | PEGBOVIGRASTIM |
|---|---|
| Modality | Recombinant protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imrestor CI brief — competitive landscape report
- Imrestor updates RSS · CI watch RSS